E8i-200
Version 1.0cc70cfa · 2026-09-13
| CAS No. | Not available |
| Chemical Name | E8i-200 |
| Synonyms | E8i200， E8i 200 |
| SMILES | CC(C)CCCCCCCCC(O)CN(CCN1CCN(CCN(CC(O)CCCCCCCCC(C)C)CC(O)CCCCCCCCC(C)C)CC1)CCN(CC(O)CCCCCCCCC(C)C)CC(O)CCCCCCCCC(C)C |
| Formula | C75H155O5N5 |
| M.Wt | 1,207.10 |
| Purity | Not available |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
E8i-200 is a novel Branched Endosomal Disruptor (BEND) ionizable lipid, designed to enhance the efficiency of lipid nanoparticles (LNPs) in drug delivery, particularly for mRNA and protein delivery. Its unique structure, featuring terminal branching, improves endosomal escape, a critical step in the delivery of therapeutic cargo into cells.E8i-200 is designed to enhance endosomal escape, a key bottleneck in mRNA and protein delivery. Its terminal branching structure provides several advantages:Improved Endosomal Membrane Penetration: The branched structure allows E8i-200 to more effectively disrupt endosomal membranes, facilitating the release of mRNA and proteins into the cytoplasm.Enhanced Gene Editing Efficiency: E8i-200 has been shown to significantly improve the delivery of CRISPR-Cas9 ribonucleoprotein (RNP) complexes, enabling efficient gene editing in vivo.E8i-200 significantly enhanced mRNA expression in the liver, outperforming traditional linear lipids like C12-200 in mouse models.E8i-200 effectively delivered CRISPR-Cas9 RNP complexes, achieving high editing efficiency in the liver, surpassing that of linear lipids.E8i-200 also showed high transfection efficiency and low cytotoxicity in T cells, making it a promising candidate for CAR-T cell engineering and other immunotherapies.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →